ArticleMaterials today. Bio2025
GPx-mimetic selenium-enriched yeast nanozymes ameliorate diabetic bone disease via dual-targeting of ROS scavenging and angiogenesis-osteogenesis coupling.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Temporal-responsive hydrogels reprogramming energy metabolic pathway in the bone-angiogenic cascade for diabetic bone regeneration.Materials today. Bio · 2026Article
- Review
- Age-related GSS promoter methylation in BMSCs drives osteoporosis and the reversal by targeted GSH delivery.Bioactive materials · 2026Article
- Sequential polarization of macrophages: an immunomodulatory strategy for novel bone repair materials.Regenerative biomaterials · 2026Review
- Recent Advances in Nanozymes Toward Diabetic Foot Ulcers.International journal of nanomedicine · 2026Review
- Nanozymes for Bone Regeneration: Mechanistic Insights into Immune and Metabolic Microenvironment Modulation.International journal of nanomedicine · 2026Review
- Advances in biomedical applications of Se-based nanozymes.Journal of nanobiotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic bone disease (DBD) is a severe skeletal complication arising from metabolic dysregulation and redox imbalance during diabetes progression. Its core pathological mechanism involves reactive oxygen species (ROS)-mediated decoupling of angiogenesis-osteogenesis, yet no targeted therapies exist. Herein, we present a biosynthesis strategy to engineer selenium-doped carbon quantum dots (SeYCQDs) from selenium-enriched yeast (SeY) as a bifunctional nanozyme for DBD treatment. By leveraging the bioconversion process of SeY, inorganic selenium is biotransformed into organoselenium metabolites, followed by hydrothermal synthesis to fabricate SeYCQDs with glutathione peroxidase (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.